Bayer's Next Act Rests on Two Fronts: A Stroke Drug and a Smarter Wheat Spray

Bayer has given investors two fresh reasons to look past the patent cliff that has shadowed its pharmaceutical division. The more consequential of the pair arrived on Tuesday, when the US Food and Drug Administration cleared Asundexian under the brand name Sunharbo to lower the risk of recurrent stroke in certain adults, used alongside an antiplatelet therapy. Bayer bills it as the first factor-XIa inhibitor approved in the United States.

The strategic weight of that green light comes from the job Bayer has assigned the drug: helping to plug the revenue hole left by Xarelto's loss of patent protection. That framing turns the approval into a test of a broader question hanging over the pharma business — how convincingly can new medicines replace sales that are slipping away?

Shipping of Sunharbo is expected to begin between mid and late November, a timeline that moves the story from regulatory milestone to commercial reality. Whether the approval translates into durable demand is the yardstick by which the economic payoff should be judged. Reuters linked a temporary share-price gain on Tuesday to the clearance, a reaction that is easy to understand once the regulatory hurdle has been cleared — though the drug's actual contribution to the business will ultimately carry more weight than the headline.

A Second Approval Widens the Picture

Asundexian does not stand alone in Bayer's recent run of news. On 4 November the company reported Chinese approval of Sevabertinib as a first-line treatment for adults with advanced HER2-mutated non-small cell lung cancer. The genetic targeting is built into the approved indication, reinforcing the case for an expanding drug portfolio — provided Bayer can convert the approval into commercially successful use.

Should investors sell immediately? Or is it worth buying Bayer?

Read together, the two decisions bolster the optimistic case, since Bayer can now point to regulatory progress across different medicines. They support the pipeline story to the extent that each treatment area eventually generates meaningful business. The pair should be seen as mutual reinforcement rather than as interchangeable wins, given their distinct medical fields.

Precision as the Common Thread

A third announcement rounds out the sequence, and it comes from an entirely different part of the company. On 5 November Bayer unveiled PrediView, a digital crop-protection concept for winter wheat. Set against the drug approvals it may sound like a footnote, but it offers a useful lens on the equity: concrete applications tie the recent product news together.

PrediView is designed to combine field-specific forecasts with a matched fungicide strategy for the 2027 season, so that digital information flows directly into the choice of a crop-protection plan. The parallel with the pharma side is the move toward more narrowly tailored uses — individual fields in one case, clearly defined patient groups and treatment goals in the other. The development stages differ, and that distinction matters: PrediView is announced for a future season, while both medicines already hold approvals. Each application area must still prove itself at the next economic stage.

The Accounts Provide the Counterweight

What turns a string of product announcements into a convincing investment case? For Bayer, the link to current trading is decisive. New offerings count in the company's favour when their commercial execution supports operating performance — which is why revenue, earnings and financing belong alongside the product headlines.

In the third quarter of 2026 Bayer posted group revenue of EUR 10.053 billion and EBITDA before special items of EUR 1.615 billion. Both figures rose, giving the recent product progress a positive reference point.

Adding to that, Bayer lifted its annual outlook last week, raising expectations for the Pharmaceuticals margin, group EBITDA before special items and free cash flow, while holding out the prospect of lower net financial debt at year-end. Higher earnings targets and an improved expected cash inflow give the product story a financial foundation — provided the company delivers on the upgraded guidance.

Bayer at a turning point? This analysis reveals what investors need to know now.

A Cautious Yardstick From the Sell Side

Media reports indicate Jefferies kept its rating at "Hold" with a price target of EUR 48.50 on Tuesday, even as the house described the US approval of Asundexian as reducing risk in Bayer's pharma pipeline. That combination makes for a sensible benchmark: the approval reflects well on Bayer, while the scale of its economic contribution is likely to determine any re-rating. A positive operating development and a restrained valuation can coexist.

The shares have already climbed 55% since the start of the year, which raises the bar for further progress. Additional optimism, in other words, will eventually need results to match.

On balance, the positive outweighs the negative in the latest approval news. Bayer has been handed a concrete opportunity to advance the revenue replacement its pharma business needs. A sustainably more favourable view of the company is warranted if Sunharbo seizes that opportunity in the market and the other approval gains translate into economic benefit as well. The operative execution — across both the laboratory and the wheat field — remains the measure by which the stock will be judged.

Ad

Bayer Stock: New Analysis - 12 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...